Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

Nanjing University School of Medicine

Status

Completed

Conditions

Idiopathic Membranous Nephropathy

Treatments

Drug: Tacrolimus

Study type

Interventional

Funder types

Other

Identifiers

NCT00302523

NJCT-0603

Details and patient eligibility

About

The purpose of this study is:

To explore the potential role of tacrolimus in the treatment of membranous nephropathy.
To investigate the safety and tolerability of tacrolimus vs methylprednisolone plus cyclophosphamide.

Full description

Idiopathic membranous nephropathy is the most common cause of nephrotic syndrome in adults. Over the past decade, a number of studies have reported therapeutic efficacy for treatment with Cyclosporine-A (CSA) in patients with nephrotic syndrome including patients with membranous nephropathy. This study will evaluate the safety and effectiveness of a new calcineurin immunosuppressive drug, tacrolimus (FK506), in reducing the amount of protein in the urine in patients with membranous nephropathy. Forty patients with biopsy-proven membranous nephropathy will be recruited. Candidates must have completed at least six month of treatment with a stable dose of angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). They will be screened with a medical history, physical examination, blood tests, and an examination for infection, cancers, and other conditions that can cause membranous nephropathy. The investigators plan to conduct an open-label study of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy. They will be treated with oral tacrolimus for 6 months, followed by 6 months of maintenance. Proteinuria, renal function will be monitored. Complete remission is defined as 24-hour urinary protein excretion to less than 0.4 mg/day. This study will explore the potential role of tacrolimus in the treatment of membranous nephropathy, which is usually resistant to conventional therapy.

Enrollment

16 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Biopsy-proven idiopathic membranous nephropathy
Nephrotic syndrome with proteinuria ( > 4 g/day) and serum albumin < 30 g/dl
Age 18-60 years with informed consent

Exclusion criteria

Patient with abnormal liver function tests
Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil, levamisole, methotrexate, or nitrogen mustard in the last 90 days
Active/serious infection
Patient with hepatitis B surface antigen or who is hepatitis C antibody positive
Patient who is diabetic
Patient is allergic or intolerant to macrolide antibiotics or tacrolimus